Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacytidine + GM-CSF in Low/Int-1 Risk MDS
NCT01542684Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2012
- Primary completion
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and sargramostim in myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 8 weeks. Started Mar 2012; status: terminated.
02
Drugs
azacitidinesargramostim
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01542684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01542684.